Sidanis Pharma

Executive Summary

Sidanis Pharma is a Berlin-based biopharmaceutical start-up founded in 2018, dedicated to developing next-generation anti-infectives that harness the host's immune system to combat infectious diseases in humans and animals. The company's innovative approach aims to overcome antibiotic resistance by enabling the immune system to more effectively detect and eliminate pathogens. While still in early stages with no disclosed pipeline or funding details, Sidanis represents a novel strategy in the anti-infective space, focusing on host-directed therapies. Given the global urgency of antimicrobial resistance, Sidanis's technology could address significant unmet medical needs if successfully validated.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate selection and preclinical data release40% success
• Q4 2026Series A funding round announcement50% success
• Q1 2027Proof-of-concept animal study results30% success